News
CMPS
9.02
+4.70%
0.41
Compass Pathways submitts NDA to FDA for COMP360 psilocybin
TipRanks · 3h ago
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), COMPASS Pathways (CMPS) and Zenas BioPharma, Inc. (ZBIO)
TipRanks · 3h ago
Compass Pathways Submits FDA New Drug Application For Comp360 Psilocybin For Treatment-Resistant Depression
Benzinga · 3h ago
Compass Pathways Price Target Maintained With a $65.00/Share by HC Wainwright & Co.
Dow Jones · 3h ago
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $65 Price Target
Benzinga · 4h ago
Weekly Report: what happened at CMPS last week (1102-1106)?
Weekly Report · 6h ago
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
Barchart · 9h ago
Compass Pathways’ Commercial Preparation Supports Outlook Despite Price-Target Cut to $16
TipRanks · 2d ago
COMPASS Pathways Stock In Focus As FDA Filing Nears Completion
Simply Wall St · 3d ago
Psychedelic: Compass Pathways beats Q3 loss estimate
TipRanks · 3d ago
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 3d ago
COMPASS Pathways (CMPS) Nears COMP360 NDA Submission, Is It Still A Bargain?
Simply Wall St · 4d ago
Compass Pathways Price Target Cut to $10.00/Share From $13.00 by Wells Fargo
Dow Jones · 4d ago
Compass Pathways Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 4d ago
Wells Fargo Maintains Equal-Weight on Compass Pathways, Lowers Price Target to $10
Benzinga · 4d ago
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), COMPASS Pathways (CMPS) and NRX Pharmaceuticals (NRXP)
TipRanks · 4d ago
Compass Pathways’ Regulatory Progress and COMP360 Launch Readiness Support Buy Rating; $25 Price Target Unchanged
TipRanks · 5d ago
Wells Fargo Sticks to Their Hold Rating for COMPASS Pathways (CMPS)
TipRanks · 5d ago
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
Barchart · 5d ago
Compass Pathways: 3 Key Takeaways for Long-Term Investors
NASDAQ · 5d ago
More
Webull provides a variety of real-time CMPS stock news. You can receive the latest news about Compass Pathways Plc through multiple platforms. This information may help you make smarter investment decisions.
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.